Home World News FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle Cell... World News FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle Cell Lymphoma By Ogkologos - February 21, 2025 1066 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ECHO study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR The Cancer Moonshot: A Midpoint Progress Update January 11, 2021 Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into... August 3, 2026 Pembrolizumab Plus Chemoradiotherapy Significantly Improves OS in Patients with Locally Advanced... October 11, 2024 Second-line Sintilimab Improves Survival Over Docetaxel in Squamous Non-Small Cell Lung... December 11, 2020 Load more HOT NEWS Why we need to continue to advocate for global tobacco control ΣΤΑΤΙΣΤΙΚΑ For Cancer Screening, COVID-19 Pandemic Creates Obstacles, Opportunities Implanted “Drug Factories” Deliver Cancer Treatment Directly to Tumors
